Dominari Holdings (STU:BP2A) FCF Margin % : -628.46% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dominari Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Dominari Holdings's Free Cash Flow for the three months ended in Mar. 2024 was €-7.91 Mil. Dominari Holdings's Revenue for the three months ended in Mar. 2024 was €1.26 Mil. Therefore, Dominari Holdings's FCF Margin % for the quarter that ended in Mar. 2024 was -628.46%.

As of today, Dominari Holdings's current FCF Yield % is -218.37%.

The historical rank and industry rank for Dominari Holdings's FCF Margin % or its related term are showing as below:

STU:BP2A' s FCF Margin % Range Over the Past 10 Years
Min: -105200 Med: -9875 Max: 7.53
Current: -788.6

During the past 13 years, the highest FCF Margin % of Dominari Holdings was 7.53%. The lowest was -105200.00%. And the median was -9875.00%.

STU:BP2A's FCF Margin % is ranked worse than
72.3% of 1047 companies
in the Biotechnology industry
Industry Median: -145.04 vs STU:BP2A: -788.60

Dominari Holdings FCF Margin % Historical Data

The historical data trend for Dominari Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings FCF Margin % Chart

Dominari Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-37,987.50

-1,111.18

Dominari Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-13,957.58	-371.40	-472.56	-628.46

Competitive Comparison of Dominari Holdings's FCF Margin %

For the Biotechnology subindustry, Dominari Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dominari Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's FCF Margin % falls into.

Dominari Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Dominari Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-20.779	/	1.87
	=	-1,111.18 %

Dominari Holdings's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-7.906	/	1.258
	=	-628.46 %

Dominari Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dominari Holdings (STU:BP2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (STU:BP2A) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

DOMH:USA

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Dominari Holdings (STU:BP2A) Headlines

No Headlines